




Ausblick




■ Rekrutierung ■ Follow/Start up

* GBG sponsor; kursiv RWE




Trial Flowchart:



*per investigator decision based on clinicopathological findings or the results of any genomic signature

** AI +/-OFS during ribociclib treatment, per investigator choice thereafter

Overall study design HER2+




250 patients with stage I HER2 positive breast cancer

Patients ideally enroll prior to surgery, to start design of ctDNA tests early

Patients subsequently found to not be pathological stage I will be off-study

Overall study design TNBC with high TILs



250 patients with stage I TNBC with high TILs

Enrollment based on local TIL assessment, with central confirmation prior to ctDNA testing

Vielen Dank

Annik Rossberg und Alena Gribko
Sabine Seiler und Johannes Holtschmidt

Und das stand up Event Team der GBG

Heilung durch Innovation, Kompetenz
und Partnerschaft – führend in der
Brustkrebs-Forschung



Sponsoren

AstraZeneca 

 NOVARTIS

Stemline
A Menarini Group Company






Daiichi-Sankyo



Lilly





AMGEN



DKMS auch noch
morgen



22. Annual Scientific Meeting 2025

■ 6./7. März 2025

NEW CONGRESS CO-CHAIR



Sibylle Loibl



19th St. Gallen International Breast Cancer Conference 2025

12 – 15 March 2025, Vienna / Austria

Topic: Primary therapy of women with early breast cancer. Evidence, controversies, consensus.